எமிலி சிட்னர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from எமிலி சிட்னர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In எமிலி சிட்னர் Today - Breaking & Trending Today
Republican 2022 Hopes Run Through Districts Scarred by Covid Bloomberg 2 days ago Jonathan Levin (Bloomberg) Republicans aiming to retake the U.S. House next year will have to defend the party’s pandemic record, especially in Sun Belt districts that stand out for their grim death tolls or lackluster vaccinations. Forty-seven Democrat-held districts and 21 Republican seats are at the center of the fight. High Covid-19 death rates or low vaccine penetration stand to be issues in around 20 of them, 15 to the potential advantage of Democrats. While voters’ memories are often short, none have been through a combined public-health, economic and political crisis in such a short time. Whatever lessons they take will determine whether Democrats who as of Tuesday will have a seven-seat margin in the 435-member body can avoid the usual midterm setback for a new president’s party. ....
Demand is low for COVID-19 antibody drugs but shortages loom FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via AP) Published December 19. 2020 12:15AM By MARILYNN MARCHIONE, AP Chief Medical Writer U.S. health officials are seeing an astonishing lack of demand for COVID-19 medicines that may help keep infected people out of the hospital, drugs they rushed out to states over the past few weeks as deaths set new records. ....
Demand is low for COVID-19 antibody drugs but shortages loom Marilynn Marchione Updated: Tags: FILE - This photo provided by Eli Lilly shows the drug Bamlanivimab, the first antibody drug to help the immune system fight COVID-19. Antibodies are made by the immune system to fight the virus but it can take several weeks after infection for the best ones to form. This and a Regeneron medication aim to help right away, by supplying concentrated doses of one or two antibodies that worked best in lab tests. (Courtesy of Eli Lilly via AP) (Eli Lilly) U.S. health officials are seeing an astonishing lack of demand for COVID-19 medicines that may help keep infected people out of the hospital, drugs they rushed out to states over the past few weeks as deaths set new records. ....
Demand is low for COVID-19 antibody drugs but shortages loom Dec. 19, 2020 at 5:00 am Marilynn Marchione, AP Chief Medical Writer U.S. health officials are seeing an astonishing lack of demand for COVID-19 medicines that may help keep infected people out of the hospital, drugs they rushed out to states over the past few weeks as deaths set new records. Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from these drugs, which supply antibodies to help the immune system fight the coronavirus. Only 5% to 20% of doses the federal government allocated have been used. Ironically, government advisers met Wednesday and Thursday to plan for the opposite problem: potential future shortages of the drug as COVID-19 cases continue to rise. Many hospitals have set up lottery systems to ration what is expected to be a limited supply, even after taking into account the unused medicines still on hand. ....
10:15 EDT, 18 December 2020 U.S. health officials are seeing an astonishing lack of demand for COVID-19 medicines that may help keep infected people out of the hospital, drugs they rushed out to states over the past few weeks as deaths set new records. Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from these drugs, which supply antibodies to help the immune system fight the coronavirus. Only 5% to 20% of doses the federal government allocated have been used. Ironically, government advisers met Wednesday and Thursday to plan for the opposite problem: potential future shortages of the drug as COVID-19 cases continue to rise. Many hospitals have set up lottery systems to ration what is expected to be a limited supply, even after taking into account the unused medicines still on hand. ....